Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna Inc (NQ: MRNA )

54.63 +0.27 (+0.50%)
Official Closing Price Updated: 4:15 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Moderna Inc

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Moderna to Present at Upcoming Conferences in November 2024
Via ACCESSWIRE
Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)
From Merck & Co., Inc.
Via Business Wire
Moderna Named a Top Employer by Science for Tenth Consecutive Year
Via ACCESSWIRE
Moderna to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024
Via ACCESSWIRE
Abbas Hussain Joins Moderna's Board of Directors
Via ACCESSWIRE
Moderna R&D Day Highlights Progress and Strategic Priorities
Via ACCESSWIRE
Moderna’s Canadian Manufacturing Facility Receives Drug Establishment License From Health Canada
Via ACCESSWIRE
MRNA Investors Have Opportunity to Lead Moderna, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
MRNA Deadline: Rosen Law Firm Urges Moderna, Inc. (NASDAQ: MRNA) Stockholders With Large Losses to Contact the Firm for Information About Their Rights
From Rosen Law Firm
Via Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
IMPORTANT MRNA DEADLINE: TOP RANKED ROSEN LAW FIRM Encourages Moderna, Inc. Investors to Secure Counsel Before Important October 8 Deadline in Securities Class Action – MRNA
From The Rosen Law Firm PA
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Moderna and Cenra Healthcare Enter Joint Agreement to Promote Moderna’s mRNA Respiratory Vaccine Portfolio in Taiwan, Including COVID-19 Vaccines
Via ACCESSWIRE
MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Moderna, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
Moderna Announces First Participant Dosed in Pivotal Phase 3 Trial of Investigational mRNA Norovirus Vaccine, mRNA-1403
Via ACCESSWIRE
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Moderna, Inc. Investors to Secure Counsel Before Important October 8 Deadline in Securities Class Action – MRNA
From The Rosen Law Firm PA
Via GlobeNewswire
MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Moderna, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
3 Beaten-Down Stocks Ready for a Comeback
if you're looking for a way to escape the market volatility, here are three stocks that are trading near their 52-week lows with solid catalysts for growth 
Via MarketBeat
Topics Economy
Exposures Economy
Moderna, Inc. REMINDER – MRNA Stockholders Should Contact Robbins LLP for Information About the Moderna, Inc. Class Action and Pending Lead Plaintiff Deadline
From Robbins LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Moderna Receives Health Canada Approval For Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older
Via ACCESSWIRE
MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Moderna, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
Moderna’s Recent Drop: 4 Reasons Bulls See Opportunity
Moderna Inc. (NASDAQ: MRNA) made headlines during the pandemic for its messenger ribonucleic acid (mRNA) technology used in its COVID-19 vaccine Spikevax. 
Via MarketBeat
Exposures COVID-19 Product Safety
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Moderna, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRNA
From The Rosen Law Firm PA
Via GlobeNewswire
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.